Radicava development continues with first ASEAN approval

17 July 2020

The first new product for amyotrophic lateral sclerosis (ALS) in decades has won approval in Indonesia, several years after it was first given marketing authorization, in Japan.

Developed by Mitsubishi Tanabe Pharma (TYO: 4508), edaravone will be marketed as Radicava in Indonesia, the same brand name that is used in the USA. In Japan the therapy is sold as Radicut.

ALS is an idiopathic neurodegenerative disease in which motor neurons selectively degenerate and vanish. While there is no cure, the approval of Radicava has brought hope that the progression of the disease may be delayed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK